NettetThe primary analysis of MOUNTAINEER (NCT03043313) in cohorts A+B treated with tucatinib (TUC) + trastuzumab (Tras) was previously reported and showed tolerability … NettetMOUNTAINEER is a global, multi-center, open-label, phase 2 trial that enrolled pts with HER2+ RAS WT mCRC previously treated with fluoropyrimidine, oxaliplatin, irinotecan, and anti-VEGF mAb. Overall, 117 pts were enrolled or randomized to receive TUC + T (cohorts A [n=45] and B [n=41]) or TUC monotherapy (cohort C [n=31]).
FDA Approves Tucatinib Plus Trastuzumab for RAS Wild-Type, …
NettetRT @pashtoonkasi: One of the most important findings unveiled @ESMOWorldGI. 🎯 #HER2⛔️in #ColorectalCancer #Mountaineer🏔study with 💊 TUCATINIB … NettetAndré T et al. Trifluridine-tipiracil plus bevacizumab versus capecitabine plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer ineligible for intensive therapy (SOLSTICE): A randomised, open-label phase 3 study. Lancet Gastroenterol Hepatol 2024;8(2):133-44.Abstract. Bekaii-Saab TS et al. MOUNTAINEER-03: Phase 3 … by my side the produxer mix
Dual HER2 Blockade in Patients With HER2-Amplified Metastatic …
Nettet12. apr. 2024 · Investigators have also observed promising data within other subsets of CRC, Hays says. In the phase 3 BEACON CRC trial, patients treated with cetuximab (Erbitux) plus encorafenib (Braftovi; n ... Nettet24. mai 2024 · Treatment with tucatinib (Tukysa) and trastuzumab (Herceptin) in patients with previously treated HER2-positive metastatic colorectal cancer yielded promising responses, according to topline findings from the phase 2 MOUNTAINEER trial (NCT03043313). 1. The primary end point of confirmed objective response rate (ORR) … Nettet28. okt. 2024 · Please expand on the trial design and patient population of MOUNTAINEER. MOUNTAINEER was an open-label, global, phase 2 study. It … by my side on my side